AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26600270 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 35
Study 25170878 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D film
Number of subjects: 408
Study 25170878 — intervention group
Group type: COMPARATOR
Intervention: 2D film
Number of subjects: 408
Study 22136163 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa intestinal gel
Number of subjects: 10
Study 22136163 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa/entacapone
Number of subjects: 10
Study 22136163 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa/tolcapone
Number of subjects: 10
Study 20659358 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable sutures
Number of subjects: 100
Study 20659358 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable sutures
Number of subjects: 100
Study 17703895 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 esc.BEACOPP + RT (arm A)
Number of subjects: 1661
Study 17703895 — intervention group
Group type: EXPERIMENTAL
Intervention: 4+4BEACOPP + RT (arm C)
Number of subjects: 1661
Study 17703895 — intervention group
Group type: COMPARATOR
Intervention: 8 esc.BEACOPP non‐RT (arm B)
Number of subjects: 1661
Study 17703895 — intervention group
Group type: COMPARATOR
Intervention: 4+4BEACOPP non‐RT (arm D)
Number of subjects: 1661
Study 17703895 — intervention group
Group type: COMPARATOR
Intervention: Overall (RT vs non-RT)
Number of subjects: 1661
Study 16301268 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural stimulation test (EST)
Number of subjects: 218
Study 16301268 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural pressure waveform analysis (EPWA)
Number of subjects: 218
Study 16301268 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EST and EPWA
Number of subjects: 218
Study 16301268 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural stimulation test (EST) with sensory response
Number of subjects: 218
Study 16301268 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural pressure waveform analysis (EPWA) by age group
Number of subjects: 218
Study 11925136 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic paracervical lymphadenectomy
Number of subjects: 95
Study 11925136 — intervention group
Group type: COMPARATOR
Intervention: Modified radical hysterectomy without paracervical dissection
Number of subjects: 95
Study 9830578 — intervention group
Group type: EXPERIMENTAL
Intervention: Banding ligation
Number of subjects: 40
Study 9830578 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 40
Study 9830578 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 7852210 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) for treating maternal pregnancy anemia; specific dosage and duration not mentioned.
Number of subjects: 0
Study 2800975 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with nitrous oxide
Number of subjects: 2
Study 2800975 — intervention group
Group type: COMPARATOR
Intervention: Enflurane with nitrous oxide
Number of subjects: 2
Study 1006255 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 43-715 (nonsteroid anti-inflammatory agent)
Number of subjects: 0
Study 1006255 — intervention group
Group type: COMPARATOR
Intervention: Collagen
Number of subjects: 0
Study 1006255 — intervention group
Group type: COMPARATOR
Intervention: Same volunteers (4 and 8 weeks later)
Number of subjects: 0
Study 30593158 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus a therapeutic education program (TENS-TEP group)
Number of subjects: 97
Study 30593158 — intervention group
Group type: COMPARATOR
Intervention: Routine care (TENS group)
Number of subjects: 97
Study 30593158 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS-TEP group
Number of subjects: 97
Study 30593158 — intervention group
Group type: COMPARATOR
Intervention: TENS group
Number of subjects: 97
Study 30593158 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study 28242040 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment
Number of subjects: 51
Study 28242040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 25762461 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cilengitide (2000 mg 2×/wk; n = 88)
Number of subjects: 265
Study 25762461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cilengitide (2000 mg 5×/wk during wk 1‐6, thereafter 2×/wk; n = 88)
Number of subjects: 265
Study 25762461 — intervention group
Group type: COMPARATOR
Intervention: Control arm (chemoradiotherapy alone; n = 89)
Number of subjects: 265
Study 23650397 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK650394 (small molecule inhibitor for SGK1)
Number of subjects: 0
Study 23650397 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK650394
Number of subjects: 0
Study 23650397 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK650394 combined with RU486 (GR antagonist)
Number of subjects: 0
Study 23650397 — intervention group
Group type: COMPARATOR
Intervention: Cortisol
Number of subjects: 0
Study 23650397 — intervention group
Group type: EXPERIMENTAL
Intervention: SGK1 mRNA
Number of subjects: 0
Study 21135196 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR therapy plus traditional therapy
Number of subjects: 25
Study 21135196 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy alone
Number of subjects: 25
Study 18085737 — intervention group
Group type: EXPERIMENTAL
Intervention: HAQ-DI score calculated with aids/devices
Number of subjects: 0
Study 18085737 — intervention group
Group type: COMPARATOR
Intervention: HAQ-DI score calculated without aids/devices
Number of subjects: 0
Study 18085737 — intervention group
Group type: EXPERIMENTAL
Intervention: HAQ-DI score with aids/devices
Number of subjects: 0
Study 18085737 — intervention group
Group type: COMPARATOR
Intervention: HAQ-DI score without aids/devices
Number of subjects: 0
Study 18085737 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect Size (ES) with aids/devices
Number of subjects: 0
Study 18085737 — intervention group
Group type: COMPARATOR
Intervention: Effect Size (ES) without aids/devices
Number of subjects: 0
Study 17011443 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-pelvis radiotherapy (WP RT) + neoadjuvant and concurrent hormonal therapy (N&CHT)
Number of subjects: 649
Study 17011443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-pelvis radiotherapy (MP RT) + neoadjuvant and concurrent hormonal therapy (N&CHT)
Number of subjects: 649
Study 17011443 — intervention group
Group type: COMPARATOR
Intervention: Prostate-only radiotherapy (PO RT) + neoadjuvant and concurrent hormonal therapy (N&CHT)
Number of subjects: 649
Study 14693171 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 103
Study 14693171 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcal infection
Number of subjects: 103
Study 14693171 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 103
Study 11766085 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel cleansing plus oral antimicrobial prophylaxis with kanamycin and erythromycin for 2 days prior to surgery (group 2)
Number of subjects: 143
Study 11766085 — intervention group
Group type: COMPARATOR
Intervention: Mechanical bowel cleansing with polyethylene glycol alone (group 1)
Number of subjects: 143
Study 9028540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone treatment
Number of subjects: 69
Study 9028540 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 69
Study 8273859 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin 1 g intravenously every 8 hours for 48 hours (8 doses, n = 425)
Number of subjects: 702
Study 8273859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 1.5 g 1 hour prior to surgery plus 1.5 g every 12 hours for 3 additional doses (4 doses, n = 277)
Number of subjects: 702
Study 8273859 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 702
Study 8273859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 702
Study 3446308 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 64
Study 3446308 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine (high dose)
Number of subjects: 64
Study 2706320 — intervention group
Group type: EXPERIMENTAL
Intervention: BY912 400 mg theophylline capsules
Number of subjects: 12
Study 2706320 — intervention group
Group type: COMPARATOR
Intervention: Theo-24 capsules
Number of subjects: 12
Study 31767473 — intervention group
Group type: EXPERIMENTAL
Intervention: IGRT-R (reduced CTV-PTV margins)
Number of subjects: 3216
Study 31767473 — intervention group
Group type: EXPERIMENTAL
Intervention: IGRT-S (standard CTV-PTV margins)
Number of subjects: 3216
Study 31767473 — intervention group
Group type: COMPARATOR
Intervention: No IGRT
Number of subjects: 3216
Study 29920123 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucan and vitamin D supplementation
Number of subjects: 52
Study 29920123 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D and placebo
Number of subjects: 52
Study 29920123 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D alone
Number of subjects: 52
Study 28441573 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings with symbolic imagery
Number of subjects: 2044
Study 28441573 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings with graphic images of health effects
Number of subjects: 2044
Study 28441573 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings with personalized graphic images plus a personal testimonial
Number of subjects: 2044
Study 28441573 — intervention group
Group type: COMPARATOR
Intervention: Text-only warnings
Number of subjects: 2044
Study 28441573 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings (general)
Number of subjects: 2044
Study 26524818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided IUI (USG)
Number of subjects: 130
Study 23228670 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.1mg (Group A)
Number of subjects: 90
Study 23228670 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 10 μg (Group B)
Number of subjects: 90
Study 23228670 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 10 μg + bilateral TAP block (Group C)
Number of subjects: 90
Study 21310284 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA, 10 mg/day)
Number of subjects: 187
Study 21310284 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA, 50 mg/day)
Number of subjects: 187
Study 21310284 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CMA and CPA
Number of subjects: 187
Study 19797305 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 36
Study 19797305 — intervention group
Group type: COMPARATOR
Intervention: Stationary bicycle
Number of subjects: 36
Study 19797305 — intervention group
Group type: COMPARATOR
Intervention: Low back extension exercises
Number of subjects: 36
Study 16949079 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of pressure ulcer diagnosis and grading using a 4-grade scale based on 50 images from foot/heel and 50 images from buttock/hip regions.
Number of subjects: 7
Study 16949079 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of pressure ulcer diagnosis in the buttock/hip region.
Number of subjects: 7
Study 16949079 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of pressure ulcer grading in the buttock/hip region.
Number of subjects: 7
Study 16949079 — intervention group
Group type: COMPARATOR
Intervention: Comparison of agreement levels between nurses and physicians.
Number of subjects: 7
Study 12869082 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 287
Study 12869082 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg twice daily plus 20 mg of omeprazole daily
Number of subjects: 287
Study 10597744 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential intensification program (SEQ‐INT)
Number of subjects: 162
Study 10597744 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy regimen (CMF)
Number of subjects: 162
Study 10597744 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational crossing program (ROT‐CROSS)
Number of subjects: 162
Study 8983396 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro‐SorbTM liquid
Number of subjects: 8
Study 8983396 — intervention group
Group type: COMPARATOR
Intervention: Clinoril tablets
Number of subjects: 8
Study 1756943 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation
Number of subjects: 0
Study 7044412 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% tolmetin
Number of subjects: 100
Study 7044412 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% prednisolone
Number of subjects: 100
Study 7044412 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 100
Study 31951030 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 102
Study 31951030 — intervention group
Group type: COMPARATOR
Intervention: Unfractioned heparin (UFH)
Number of subjects: 102
Study 30863028 — intervention group
Group type: EXPERIMENTAL
Intervention: CAU + NFT (20 sessions of 30 minutes each, 2‐3 sessions per week)
Number of subjects: 119
Study 30863028 — intervention group
Group type: COMPARATOR
Intervention: CAU + exergame‐based training
Number of subjects: 119
Study 30863028 — intervention group
Group type: COMPARATOR
Intervention: CAU (no active treatment)
Number of subjects: 119
Study 28400200 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral and bilateral constant-current DBS of the ventralis intermedius (VIM) nucleus of the thalamus
Number of subjects: 127
Study 28400200 — intervention group
Group type: EXPERIMENTAL
Intervention: Second contralateral VIM-DBS
Number of subjects: 127
Study 26143052 — intervention group
Group type: EXPERIMENTAL
Intervention: Active neurodynamic mobilization program
Number of subjects: 48
Study 26143052 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 23593932 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg per day maximum)
Number of subjects: 18
Study 23593932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21219094 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI simulation (n=59)
Number of subjects: 99
Study 21219094 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 99
Study 21219094 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe TBI (n=38)
Number of subjects: 99
Study 19798507 — intervention group
Group type: EXPERIMENTAL
Intervention: PPH
Number of subjects: 41
Study 19798507 — intervention group
Group type: EXPERIMENTAL
Intervention: THD
Number of subjects: 41
Study 16508555 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity numerical rating scale (PI‐NRS)
Number of subjects: 442
Study 16508555 — intervention group
Group type: EXPERIMENTAL
Intervention: Quebec Back Pain Disability Scale (QBPDS)
Number of subjects: 442
Study 16508555 — intervention group
Group type: EXPERIMENTAL
Intervention: Euroqol (EQ)
Number of subjects: 442
Study 14987306 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg once daily
Number of subjects: 100
Study 14987306 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg once daily plus cetirizine (CTZ) 10 mg
Number of subjects: 100
Study 14987306 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg once daily plus montelukast (MSK) 10 mg
Number of subjects: 100
Study 14987306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (CTZ) 10 mg plus montelukast (MSK) 10 mg
Number of subjects: 100
Study 14987306 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 100
Study 14987306 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (FPANS, FPANS plus CTZ, FPANS plus MSK, CTZ plus MSK)
Number of subjects: 100
Study 15101888 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25-microg/h patch with local heat
Number of subjects: 6
Study 15101888 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 25-microg/h patch without local heat
Number of subjects: 6
Study 8697308 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg ramipril
Number of subjects: 5
Study 8697308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 1449332 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic AV delay (linear reduction from 156 ms to 84 ms)
Number of subjects: 10
Study 6141724 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin and polythiazide
Number of subjects: 20
Study 6141724 — intervention group
Group type: COMPARATOR
Intervention: Nadolol and polythiazide
Number of subjects: 20
Study 30888908 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Number of subjects: 29
Study 30888908 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined locoregional and systemic therapy
Number of subjects: 29
Study 30888908 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional therapy alone
Number of subjects: 29
Study 30888908 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status (PS) ≥2
Number of subjects: 29
Study 30888908 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, extrapericardial disease, and NPE at progression
Number of subjects: 29
Study 29877727 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for pediatric anxiety disorders
Number of subjects: 488
Study 28594776 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic sling
Number of subjects: 597
Study 28594776 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator sling
Number of subjects: 597
Study 28594776 — intervention group
Group type: COMPARATOR
Intervention: Both sling types
Number of subjects: 597
Study 26530743 — intervention group
Group type: EXPERIMENTAL
Intervention: 34 Gy in 1 fraction (arm 1)
Number of subjects: 94
Study 26530743 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 Gy in 4 consecutive daily fractions (arm 2)
Number of subjects: 94
Study 24084072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 168
Study 24084072 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 168
Study 21961181 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide induction therapy
Number of subjects: 85
Study 21961181 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 85
Study 19005931 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 190
Study 19005931 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility
Number of subjects: 190
Study 17345835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 105
Study 17345835 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole
Number of subjects: 105
Study 14558437 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophyllin 400 retard Heumann (formulation A) - 400 mg once daily
Number of subjects: 24
Study 14558437 — intervention group
Group type: COMPARATOR
Intervention: Oral solution (formulation B) - 133 mg t.i.d.
Number of subjects: 24
Study 14558437 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline sustained release formulation C - 375 mg once daily
Number of subjects: 24
Study 10895372 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient antioxidants (selenium, beta-carotene, vitamin C, vitamin E, and methionine) with allopurinol
Number of subjects: 33
Study 10895372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 9487832 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Interclean‐ID2 with Flexi‐Tip gingival massage attachment
Number of subjects: 59
Study 9487832 — intervention group
Group type: COMPARATOR
Intervention: Manual floss
Number of subjects: 59
Study 7691604 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloids
Number of subjects: 29
Study 7691604 — intervention group
Group type: COMPARATOR
Intervention: Crystalloids and dextran 70
Number of subjects: 29
Study 3544597 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 34
Study 3544597 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic prophylaxis)
Number of subjects: 34
Study 31902935 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Program for Promoting Appropriate Self-medication via Pharmacies and Pharmacists
Number of subjects: 62
Study 31902935 — intervention group
Group type: COMPARATOR
Intervention: Medication/health class (control group)
Number of subjects: 62
Study 30409202 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week, task-specific training program on an exergame-based balance training system (Physiomat®), 2 times per week
Number of subjects: 56
Study 27748249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep group (participants who slept after film viewing)
Number of subjects: 65
Study 27748249 — intervention group
Group type: COMPARATOR
Intervention: Wake group (participants who remained awake after film viewing)
Number of subjects: 65
Study 25262434 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5 mg/day)
Number of subjects: 75
Study 25262434 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 75
Study 22661587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 361
Study 22661587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 22661587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (RPSFT analysis)
Number of subjects: 361
Study 20578283 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% preserved with 0.005% BAK
Number of subjects: 106
Study 20578283 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% preserved with 0.02% BAK
Number of subjects: 106
Study 20578283 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% preserved with sofZia
Number of subjects: 106
Study 19025535 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal midazolam (50 microg/kg) combined with 0.2% ropivacaine
Number of subjects: 60